看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
- u( X- r! l( p& u+ S' q. k$ }7 \5 W
+ f* p% y8 T4 V& f$ ACurrently available feasibility data for possible combination strategies.
F. A$ j) r# N4 C# q' M————————————————————————————————
5 n7 f3 R9 ?: @% }4 u! R' QCombination Feasibility according to preliminary data
, `: X( E, `1 s: R4 T6 A& Y——————————————————————————————————7 R/ f8 g' v+ n( Z; G7 n
Bevacizumab + sorafenib Yes, reduced dose 2 U7 `. y! W: U4 r6 b% N$ h+ F
Bevacizumab + sunitinib† No ' X: }) r/ i3 i$ O5 g+ m l
Bevacizumab + temsirolimus Yes
9 ^; H* c5 s! F- YBevacizumab + everolimus Yes % ~4 s: Y+ l& q6 v% U* k7 N1 F I
Sorafenib + sunitinib ?
4 ` k' ?: E2 H4 M! E1 q" X/ D' SSorafenib + temsirolimus Yes, reduced dose
0 k& ], I# R& G& b! kSorafenib + everolimus Yes, reduced dose
% \7 J. A, A! X5 ySunitinib + temsirolimus† No
3 s5 z: i! M2 f) t0 ]4 ?Sunitinib + everolimus ?
" v7 B5 G3 G# n6 G, [) vTemsirolimus + everolimus ? 3 q+ C9 ~0 h: o, R5 T/ ^6 P) p- ], W- f
————————————————————
, c! ~5 y z( x†Led to US FDA warning.
3 B! O# z, d) n?: As yet unattempted combination.) j# Z9 w' Y z9 m# n: o7 Z
|
显身卡
- K1 {0 l* S: u! x9 G
